Trials / Unknown
UnknownNCT03602638
Effects of a Dipeptidyl Peptidase-4 Inhibitor Sitagliptininsulin on the Progression of Coronary Atherosclerosis in Patients With Type 2 Diabetes
Chinese PLA General Hospital Hainan Branch
- Status
- Unknown
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 300 (estimated)
- Sponsor
- Chinese PLA General Hospital · Academic / Other
- Sex
- All
- Age
- 18 Years – 80 Years
- Healthy volunteers
- Accepted
Summary
This study was to investigate the Effect of Sitagliptin, a dipeptidyl peptidase-4 inhibitor, on progression of coronary atherosclerosis in patients with type 2 diabetes.
Detailed description
This study was to investigate the Effect of Sitagliptin, a dipeptidyl peptidase-4 inhibitor, on progression of coronary atherosclerosis in patients with type 2 diabetes.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Sitagliptin | Sitagliptin 100mg QD |
| DRUG | Acarbose | Acarbose |
Timeline
- Start date
- 2018-10-01
- Primary completion
- 2019-05-01
- Completion
- 2020-12-01
- First posted
- 2018-07-27
- Last updated
- 2018-07-27
Source: ClinicalTrials.gov record NCT03602638. Inclusion in this directory is not an endorsement.